Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491458 | 1.00 | MDM4 (0.55) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL1491454 | 1.00 | MDM4 (0.55) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL29401132 | 1.00 | MDM4 (0.55) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL29400299 | 1.00 | MDM4 (0.55) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL4404683 | 0.91 | PTPN1 (0.49) | MDM4TP53SLC17A5 | |
| SCHEMBL12088806 | 0.90 | MDM4 (0.48) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL3492803 | 0.89 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL10020438 | 0.89 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL1739174 | 0.89 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL22636161 | 0.89 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858538-B1 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS LTD (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3347372-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | Aileron Therapeutics, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9598463-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2017044633-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20160287563-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287563-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-7524926-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2009-04-28 | — | — | US | disclosed |
| CN-101146545-A | Mucin hypersecretion inhibitors based on the structure of MANS and methods of use | BIOMARCK PHARMACEUTICALS LTD (US) | 2008-03-19 | — | — | CN | disclosed |
| US-20060205664-A1 | Mucin hypersecretion inhibitors and methods of use | WILLIAMS, MASON L. | 2006-09-14 | — | — | US | disclosed |
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
| US-6372883-B1 | FOR THERAPY AND PROPHYLAXIS OF INFECTIONS CAUSED BY HEPATITIS C, HEPATITIS G AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2002-04-16 | — | — | US | disclosed |
| US-5861477-A | POLYPEPTIDES AS TISSUE PLASMINOGEN ACTIVATOR | ATASSI M ZOUHAIR (US) | 1999-01-19 | — | — | US | disclosed |
| US-5759834-A | SYNTHETIC POLYPEPTIDE AS CATALYST | ATASSI M ZOUHAIR (US) | 1998-06-02 | — | — | US | disclosed |
| US-5576216-A | Universal standard reagents, method of preparing same and use thereof | Patchornik, Zipora (IL) | 1996-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | MDM4 3716/4885TP53 3089/4885SLC17A5 2659/4885 |
| US-20160287563-A1 | Cysteine Prodrugs | SLC7A11, GCLC, CTH | MDM4 2572/4885TP53 1421/4885SLC17A5 1110/4885 |
| US-20160081987-A1 | Cysteine Prodrugs | SLC7A11, GCLC, CTH | MDM4 2572/4885TP53 1421/4885SLC17A5 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.